MX2019002097A - Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. - Google Patents
Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer.Info
- Publication number
- MX2019002097A MX2019002097A MX2019002097A MX2019002097A MX2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A MX 2019002097 A MX2019002097 A MX 2019002097A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- receptor antagonists
- androgen receptor
- subject
- Prior art date
Links
- 229940123407 Androgen receptor antagonist Drugs 0.000 title abstract 2
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000003936 androgen receptor antagonist Substances 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377932P | 2016-08-22 | 2016-08-22 | |
| PCT/IB2017/055063 WO2018037342A1 (en) | 2016-08-22 | 2017-08-22 | Thiohydantoin androgen receptor antagonists for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019002097A true MX2019002097A (es) | 2019-05-15 |
Family
ID=60009664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019002097A MX2019002097A (es) | 2016-08-22 | 2017-08-22 | Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209539A1 (enExample) |
| EP (1) | EP3500259A1 (enExample) |
| JP (1) | JP2019528290A (enExample) |
| KR (1) | KR20190040030A (enExample) |
| CN (1) | CN109640986A (enExample) |
| AU (1) | AU2017316756A1 (enExample) |
| BR (1) | BR112019003406A2 (enExample) |
| CA (1) | CA3034449A1 (enExample) |
| MA (1) | MA45992A (enExample) |
| MX (1) | MX2019002097A (enExample) |
| RU (1) | RU2019108092A (enExample) |
| WO (1) | WO2018037342A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032644B (zh) * | 2017-08-07 | 2021-08-10 | 正大天晴药业集团股份有限公司 | 用作雄激素受体拮抗剂的二芳基硫代乙内酰脲化合物 |
| AU2019387367A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
| BR112021015122A2 (pt) | 2019-02-01 | 2021-09-28 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Cristal de composto de diariltio-hidantoína |
| CN115403624B (zh) * | 2022-09-30 | 2024-08-27 | 上海应用技术大学 | 一种二芳基硫代乙内酰脲化合物及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028869B1 (ru) * | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Модуляторы рецептора андрогенов и их применение |
| EP2911666B1 (en) * | 2012-10-26 | 2022-08-24 | Memorial Sloan-Kettering Cancer Center | Modulators of resistant androgen receptor |
-
2017
- 2017-08-22 EP EP17778334.7A patent/EP3500259A1/en not_active Withdrawn
- 2017-08-22 CN CN201780051671.2A patent/CN109640986A/zh active Pending
- 2017-08-22 CA CA3034449A patent/CA3034449A1/en not_active Abandoned
- 2017-08-22 BR BR112019003406-4A patent/BR112019003406A2/pt not_active Application Discontinuation
- 2017-08-22 MX MX2019002097A patent/MX2019002097A/es unknown
- 2017-08-22 MA MA045992A patent/MA45992A/fr unknown
- 2017-08-22 KR KR1020197007833A patent/KR20190040030A/ko not_active Ceased
- 2017-08-22 WO PCT/IB2017/055063 patent/WO2018037342A1/en not_active Ceased
- 2017-08-22 RU RU2019108092A patent/RU2019108092A/ru not_active Application Discontinuation
- 2017-08-22 JP JP2019510593A patent/JP2019528290A/ja active Pending
- 2017-08-22 AU AU2017316756A patent/AU2017316756A1/en not_active Abandoned
- 2017-08-22 US US16/327,703 patent/US20190209539A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018037342A1 (en) | 2018-03-01 |
| RU2019108092A (ru) | 2020-09-22 |
| US20190209539A1 (en) | 2019-07-11 |
| MA45992A (fr) | 2019-06-26 |
| JP2019528290A (ja) | 2019-10-10 |
| CN109640986A (zh) | 2019-04-16 |
| KR20190040030A (ko) | 2019-04-16 |
| AU2017316756A1 (en) | 2019-02-21 |
| BR112019003406A2 (pt) | 2019-05-21 |
| CA3034449A1 (en) | 2018-03-01 |
| RU2019108092A3 (enExample) | 2020-11-30 |
| EP3500259A1 (en) | 2019-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| PH12013501341A1 (en) | Morphinan compounds | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX393599B (es) | Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco | |
| MD20150035A2 (ro) | Inhibitori de tirozinkinaza Bruton | |
| IN2015KN00414A (enExample) | ||
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| UA117830C2 (uk) | Похідні біпіразолу як інгібітори jak | |
| MX2015012006A (es) | Inhibidores de bromodominio tetraciclicos. | |
| TN2016000057A1 (en) | Methods of treating sporadic inclusion body myositis | |
| EP2328414A4 (en) | SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES | |
| NZ726366A (en) | Syk inhibitors | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| MX2023010064A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo. | |
| MX2019002097A (es) | Antagonistas del receptor androgenico de tiohidantoina para el tratamiento del cancer. | |
| PH12020550616A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| MY199091A (en) | Therapeutic compounds | |
| MY201535A (en) | Therapeutic compounds | |
| MY189663A (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| MX2015012741A (es) | Palbociclib deuterado. | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| MX2019009586A (es) | Composiciones y metodos para tratar enfermedades asociadas con la permeabilidad del epitelio intestinal. | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| MX2024013184A (es) | Metodos y composiciones para tratar apnea del sue?o |